Literature DB >> 15385496

Sm14 of Schistosoma mansoni in fusion with tetanus toxin fragment C induces immunoprotection against tetanus and schistosomiasis in mice.

Patrícia A E Abreu1, Patrícia A Miyasato, Mônica M Vilar, Waldely O Dias, Paulo L Ho, Míriam Tendler, Ana L T O Nascimento.   

Abstract

We have constructed vectors that permit the expression in Escherichia coli of Schistosoma mansoni fatty acid-binding protein 14 (Sm14) in fusion with the nontoxic, but highly immunogenic, tetanus toxin fragment C (TTFC). The recombinant six-His-tagged proteins were purified by nickel affinity chromatography and used in immunization and challenge assays. Animals inoculated with TTFC in fusion with or coadministered with Sm14 showed high levels of tetanus toxin antibodies, while animals inoculated with Sm14 in fusion with or coadministered with TTFC showed high levels of Sm14 antibodies. In both cases, there were no changes in the type of immune response (Th2) obtained with the fusion proteins compared to those obtained with the nonfused proteins. Mice immunized with the recombinant proteins (TTFC in fusion with or coadministered with Sm14) survived the challenge with tetanus toxin and did not show any symptoms of the disease. Control animals inoculated with either phosphate-buffered saline (PBS) or Sm14 died with severe symptoms of tetanus after 24 h. Mice immunized with the recombinant proteins (Sm14 in fusion with or coadministered with TTFC) showed a 50% reduction in worm burden when they were challenged with S. mansoni cercariae, while control animals inoculated with either PBS or TTFC were not protected. The results show that the expression of other antigens in fusion at the carboxy terminus of TTFC is feasible for the development of a multivalent recombinant vaccine.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15385496      PMCID: PMC517564          DOI: 10.1128/IAI.72.10.5931-5937.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  22 in total

1.  Neutralizing antibodies and immunoprotection against pertussis and tetanus obtained by use of a recombinant pertussis toxin-tetanus toxin fusion protein.

Authors:  P Boucher; H Sato; Y Sato; C Locht
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

2.  An Escherichia coli host strain useful for efficient overproduction of cloned gene products with NaCl as the inducer.

Authors:  P Bhandari; J Gowrishankar
Journal:  J Bacteriol       Date:  1997-07       Impact factor: 3.490

3.  High-level expression of tetanus toxin fragment C-thioredoxin fusion protein in Escherichia coli.

Authors:  A V Ribas; P L Ho; M M Tanizaki; I Raw; A L Nascimento
Journal:  Biotechnol Appl Biochem       Date:  2000-04       Impact factor: 2.431

4.  Characterization of recombinant tetanus toxin derivatives suitable for vaccine development.

Authors:  D Figueiredo; C Turcotte; G Frankel; Y Li; O Dolly; G Wilkin; D Marriott; N Fairweather; G Dougan
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

5.  Expression and immunogenicity of an Echinococcus granulosus fatty acid-binding protein in live attenuated Salmonella vaccine strains.

Authors:  J A Chabalgoity; J A Harrison; A Esteves; R Demarco de Hormaeche; R Ehrlich; C M Khan; C E Hormaeche
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

6.  r-Sm14 - pRSETA efficacy in experimental animals.

Authors:  C R Ramos; M M Vilar; A L Nascimento; P L Ho; N Thaumaturgo; R Edelenyi; M Almeida; W O Dias; C M Diogo; M Tendler
Journal:  Mem Inst Oswaldo Cruz       Date:  2001       Impact factor: 2.743

7.  A Salmonella typhimurium htrA live vaccine expressing multiple copies of a peptide comprising amino acids 8-23 of herpes simplex virus glycoprotein D as a genetic fusion to tetanus toxin fragment C protects mice from herpes simplex virus infection.

Authors:  J A Chabalgoity; C M Khan; A A Nash; C E Hormaeche
Journal:  Mol Microbiol       Date:  1996-02       Impact factor: 3.501

8.  Construction, expression, and immunogenicity of the Schistosoma mansoni P28 glutathione S-transferase as a genetic fusion to tetanus toxin fragment C in a live Aro attenuated vaccine strain of Salmonella.

Authors:  C M Khan; B Villarreal-Ramos; R J Pierce; G Riveau; R Demarco de Hormaeche; H McNeill; T Ali; N Fairweather; S Chatfield; A Capron
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

9.  A Schistosoma mansoni fatty acid-binding protein, Sm14, is the potential basis of a dual-purpose anti-helminth vaccine.

Authors:  M Tendler; C A Brito; M M Vilar; N Serra-Freire; C M Diogo; M S Almeida; A C Delbem; J F Da Silva; W Savino; R C Garratt; N Katz; A S Simpson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

10.  An experimental bivalent peptide vaccine against schistosomiasis and fascioliasis.

Authors:  Mônica Magno Vilar; Frank Barrientos; Marília Almeida; Nilton Thaumaturgo; Andrew Simpson; Richard Garratt; Miriam Tendler
Journal:  Vaccine       Date:  2003-12-08       Impact factor: 3.641

View more
  6 in total

1.  A newly identified leptospiral adhesin mediates attachment to laminin.

Authors:  Angela S Barbosa; Patricia A E Abreu; Fernanda O Neves; Marina V Atzingen; Mônica M Watanabe; Mônica L Vieira; Zenaide M Morais; Sílvio A Vasconcellos; Ana L T O Nascimento
Journal:  Infect Immun       Date:  2006-09-05       Impact factor: 3.441

2.  Candidate live, attenuated Salmonella enterica serotype Typhimurium vaccines with reduced fecal shedding are immunogenic and effective oral vaccines.

Authors:  Moataz Abd El Ghany; Angela Jansen; Simon Clare; Lindsay Hall; Derek Pickard; Robert A Kingsley; Gordon Dougan
Journal:  Infect Immun       Date:  2007-02-12       Impact factor: 3.441

Review 3.  Current status of vaccines for schistosomiasis.

Authors:  Donald P McManus; Alex Loukas
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

Review 4.  Development of the Brazilian Anti Schistosomiasis Vaccine Based on the Recombinant Fatty Acid Binding Protein Sm14 Plus GLA-SE Adjuvant.

Authors:  Miriam Tendler; Marilia Almeida; Andrew Simpson
Journal:  Front Immunol       Date:  2015-05-12       Impact factor: 7.561

5.  Tetanus toxin fragment C fused to flagellin makes a potent mucosal vaccine.

Authors:  Shee Eun Lee; Chung Truong Nguyen; Soo Young Kim; Thinh Nguyen Thi; Joon Haeng Rhee
Journal:  Clin Exp Vaccine Res       Date:  2015-01-30

6.  Investigating Immunization With Nucleotide Enzymes of Schistosoma mansoni: Nucleoside Diphosphate Kinase and Adenylosuccinate Lyase as New Antigenic Targets Against Schistosomiasis.

Authors:  Túlio di Orlando Cagnazzo; Camila Tita Nogueira; Cynthia Aparecida de Castro; Débora Meira Neris; Ana Carolina Maragno Fattori; Ricardo de Oliveira Correia; Yulli Roxenne Albuquerque; Bruna Dias de Lima Fragelli; Tiago Manuel Fernandes Mendes; Silmara Marques Allegretti; Edson Garcia Soares; Larissa Romanello; Juliana Roberta Torini; Humberto D'Muniz Pereira; Fernanda de Freitas Anibal
Journal:  Front Immunol       Date:  2020-09-23       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.